JP2005537312A5 - - Google Patents

Download PDF

Info

Publication number
JP2005537312A5
JP2005537312A5 JP2004530135A JP2004530135A JP2005537312A5 JP 2005537312 A5 JP2005537312 A5 JP 2005537312A5 JP 2004530135 A JP2004530135 A JP 2004530135A JP 2004530135 A JP2004530135 A JP 2004530135A JP 2005537312 A5 JP2005537312 A5 JP 2005537312A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
alkoxy
dimethyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004530135A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005537312A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/008967 external-priority patent/WO2004018431A2/en
Publication of JP2005537312A publication Critical patent/JP2005537312A/ja
Publication of JP2005537312A5 publication Critical patent/JP2005537312A5/ja
Withdrawn legal-status Critical Current

Links

JP2004530135A 2002-08-17 2003-08-13 新規のフェナントリジン Withdrawn JP2005537312A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02018530 2002-08-17
PCT/EP2003/008967 WO2004018431A2 (en) 2002-08-17 2003-08-13 Novel phenanthridines

Publications (2)

Publication Number Publication Date
JP2005537312A JP2005537312A (ja) 2005-12-08
JP2005537312A5 true JP2005537312A5 (enExample) 2006-10-12

Family

ID=31896839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004530135A Withdrawn JP2005537312A (ja) 2002-08-17 2003-08-13 新規のフェナントリジン

Country Status (10)

Country Link
US (1) US20060116518A1 (enExample)
EP (1) EP1537086A2 (enExample)
JP (1) JP2005537312A (enExample)
AU (1) AU2003253408A1 (enExample)
CA (1) CA2495597A1 (enExample)
HR (1) HRP20050228A2 (enExample)
IS (1) IS7730A (enExample)
PL (1) PL374014A1 (enExample)
RS (1) RS20050116A (enExample)
WO (1) WO2004018431A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2496459C (en) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1720835B1 (en) * 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
MXPA06009892A (es) * 2004-03-10 2007-03-01 Altana Pharma Ag Nuevas hidroxi-6-fenilfenantridinas sustituidas con amido y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4).
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US7411093B2 (en) * 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
ES2337083T3 (es) 2005-03-02 2010-04-20 Nycomed Gmbh (2r,4ar,10br)-6-(2,6-dimetoxipiridin-3-il)-9-exoti-8-metoxi-1,2,3,4,4a,10b-hexahidrofenantridin-2-ol, sal de hc1.
AU2006221957A1 (en) * 2005-03-09 2006-09-14 Nycomed Gmbh Amido-substituted 6-phenylphenanthridines
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
HRP20120494T1 (hr) 2006-04-21 2012-08-31 Novartis Ag Derivati purina za uporabu kao agonista adenozin a2a receptora
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
AU2007342223B2 (en) 2007-01-10 2011-02-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2332933A1 (en) 2007-05-07 2011-06-15 Novartis AG Epithelial sodium channel (ENaC) inhibitors
KR101178674B1 (ko) 2007-10-04 2012-08-30 에프. 호프만-라 로슈 아게 사이클로프로필 아릴 아마이드 유도체 및 이의 용도
BRPI0820669A2 (pt) 2007-12-10 2020-08-04 Novartis Ag compostos orgânicos
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー N−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
CN103946221B (zh) 2011-09-16 2016-08-03 诺华股份有限公司 用于治疗囊性纤维化的杂环化合物
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
AU2014391610B2 (en) 2014-04-24 2018-01-25 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
CN108658778A (zh) * 2018-06-19 2018-10-16 上海华堇生物技术有限责任公司 一种3,4-二甲氧基-β-硝基苯乙烯的新制备方法
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
KR20220052934A (ko) 2019-08-28 2022-04-28 노파르티스 아게 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
EE03523B1 (et) * 1996-01-31 2001-10-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenantridiinid, neid sisaldavad ravimid ja nende kasutamine
US6127378A (en) * 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
AU753615B2 (en) * 1997-07-25 2002-10-24 Altana Pharma Ag Novel tetrazole derivatives
PT1000035E (pt) * 1997-07-25 2003-04-30 Altana Pharma Ag 6-fenilfenantridinas substituidas
ATE356810T1 (de) * 1999-01-15 2007-04-15 Altana Pharma Ag Polysubstituted 6-phenylphenanthridines mit pde- iv hemmender wirkung
DE60025327T2 (de) * 1999-01-15 2006-08-24 Altana Pharma Ag 6-arylphenanthridine mit pde-iv hemmender wirkung
EE05105B1 (et) * 1999-01-15 2008-12-15 Byk Gulden Lomberg Chemische Fabrik Gmbh Fenlfenantridiinid, nende kasutamine ravimite valmistamiseks ning neid sisaldav ravim
AU2001239550A1 (en) * 2000-03-23 2001-10-03 Takeda Chemical Industries Ltd. Furoisoquinoline derivatives, process for producing the same and use thereof
SI1303506T1 (en) * 2000-07-14 2005-06-30 Altana Pharma Ag 6-heteroarylphenanthridines
AU2001267589A1 (en) * 2000-07-14 2002-01-30 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
US6936622B2 (en) * 2001-02-21 2005-08-30 Altana Pharma Ag 6-phenylbenzonaphthyridines
AU2003255493B8 (en) * 2002-08-29 2009-03-26 Takeda Gmbh 2-hydroxy-6-phenylphenanthridines as PDE-4 inhibitors
EP1720835B1 (en) * 2004-02-18 2012-12-12 Nycomed GmbH Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiesterase (pde) 4 inhibitors

Similar Documents

Publication Publication Date Title
JP2005537313A5 (enExample)
RU2436780C2 (ru) Производные 5-фенилтиазола и их применение в качестве ингибиторов рi3 киназы
RU2019120990A (ru) Бициклические гетероарильные производные в качестве стимуляторов cftr
ATE349432T1 (de) 2-anilino-pyrimidin-derivate als cyclin-abhängige kinase hemmer
DE60142469D1 (de) Imidinderivate als antineoplastika
ES2336425T3 (es) Derivados de tiazoles utiles como agentes antiinflamatorios.
NO2015020I1 (no) Ceritinib, 5-klor-N-5-metyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oksy]fenyl-N-[2-(propan-2-sulfonyl)fenyl]pyrimidine-2,4-diamin, eller et farmasøytisk akseptabelt salt derav
JP2011515462A5 (enExample)
JP2006517572A5 (enExample)
IL175609A (en) N-acylsulfonamide apoptosis promoters for use in treating diseases during which anti-apoptotic protein family members are expressed
RU2009120389A (ru) Гетероциклические соединения в качестве противовоспалительных агентов
JP2010513322A5 (enExample)
JP2010509372A5 (enExample)
ATE327225T1 (de) Neue verwendung von benzothiazolderivaten
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
IL205501A (en) Preparation of preparations for the treatment of arthritis
JP2006515339A5 (enExample)
NO167917C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive, nye derivater av ((4-(4-(4-fenyl-1-piperazinyl)fenoksymetyl)-1,3-dioksolan-2-yl)metyl)-1h-imidazoler og -1h-1,2,4-triazoler
JP2005514420A5 (enExample)
NO20055655L (no) Anvendelse av azetidinkarboksamidderivater i terapi
JP2006507247A5 (enExample)
EP0455789B1 (en) Method of preventing or limiting reperfusion damage
JP2005538111A5 (enExample)
JP2005519885A5 (enExample)
JP2003512327A5 (enExample)